Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7344757

C=CCOc1c(OC)ccc2ccc(C(=N)N)cc12.O=C(O)C(F)(F)F

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLAU P00749 8/20 0.62
KDM4E B2RXH2 3/20 0.43
PRSS1 P07477 6/20 0.42
F2 P00734 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PLG P00747 2/20 0.40
PLAT P00750 2/20 0.40
KLK1 P06870 2/20 0.40
POLB P06746 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
PDE4B Q07343 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7333225 0.86 PLAU (0.73) PLAUPRSS1F2SMN1; SMN2PLG
Trifluoroacetic Acid SCHEMBL7345791 0.86 PLAU (0.84) PLAUPRSS1F2PLGPLAT
Trifluoroacetic Acid SCHEMBL7337301 0.85 PLAU (0.64) PLAUPRSS1F2PLGPLAT
Trifluoroacetic Acid SCHEMBL7456773 0.84 PLAU (0.70) PLAUPRSS1F2PLGPLAT
SCHEMBL7344760 0.82 PLAU (0.60) PLAUPRSS1F2PLGPLAT
Trifluoroacetic Acid SCHEMBL7344763 0.82 KDM4E (0.41) PLAUKDM4ESMN1; SMN2POLBNPC1
Trifluoroacetic Acid SCHEMBL7344754 0.82 KDM4E (0.41) PLAUKDM4ESMN1; SMN2POLBNPC1
Trifluoroacetic Acid SCHEMBL7592047 0.81 PLAU (0.56) PLAUPRSS1F2PLGPLAT
Trifluoroacetic Acid SCHEMBL7339921 0.80 PLAU (0.57) PLAUPRSS1F2PLGPLAT
Trifluoroacetic Acid SCHEMBL7339090 0.79 PLAU (0.57) PLAUPRSS1F2PLGPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885KDM4E 4285/4885PRSS1 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.